RxDoctor Payments Data

Chitralekha Kathuria, MD

Family Medicine · Tulsa, OKNPI 1336117423

Payments from drug & device makers

$11,738in general payments, 2019–2025

Across 708 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Pfizer$960
  • GSK$823
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$11,732100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,738 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$106,350
Medicare patients
341
Services billed
2,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$61,359
JardianceEmpagliflozin36$40,227
TradjentaLinagliptin61$32,921
MounjaroTirzepatide24$24,188
MyrbetriqMirabegron35$23,720
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$19,516
EliquisApixaban17$14,245
Rosuvastatin Calcium377$14,133
Breo ElliptaFluticasone/Vilanterol29$13,241
FarxigaDapagliflozin Propanediol21$11,442
JanumetSitagliptin Phos/Metformin Hcl11$8,213
Janumet XrSitagliptin Phos/Metformin Hcl15$8,019
Atorvastatin Calcium308$7,657
VascepaIcosapent Ethyl17$7,124
LinzessLinaclotide11$5,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$622$73,14797 claims
Novo NordiskOzempic$1,037$61,35965 claims
GSKTrelegy Ellipta, Breo Ellipta$823$32,75753 claims
Lilly USA, LLCMounjaro$1,357$24,18824 claims
Astellas Pharma US IncMyrbetriq$204$23,72035 claims
MerckJanumet, Janumet Xr$181$16,23226 claims
PfizerEliquis$960$14,24517 claims
AstraZenecaFarxiga$1,468$11,44221 claims
AbbVieLinzess, Synthroid$1,565$9,82182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →